Unknown

Dataset Information

0

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab.

ABSTRACT:

SUBMITTER: Stiasny K 

PROVIDER: S-EPMC9790897 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab.

Stiasny Karin K   Weseslindtner Lukas L   Heinzel Andreas A   Camp Jeremy V JV   Oberbauer Rainer R   Reindl-Schwaighofer Roman R  

Transplant international : official journal of the European Society for Organ Transplantation 20221212

Similar Datasets

Unknown Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
| S-EPMC10100701 | biostudies-literature
Unknown Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer.
| S-EPMC9501743 | biostudies-literature
Unknown Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment.
| S-EPMC9307285 | biostudies-literature
Unknown Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections.
| S-EPMC9556863 | biostudies-literature
Unknown Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
| S-EPMC9108069 | biostudies-literature
Unknown Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era.
| S-EPMC10138227 | biostudies-literature
Unknown SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.
| S-EPMC11880995 | biostudies-literature
Unknown Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
| S-EPMC9035359 | biostudies-literature
Unknown Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
| S-EPMC9135681 | biostudies-literature
Unknown Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.
| S-EPMC9258748 | biostudies-literature